Related Experiment Video
Updated: Jun 19, 2026
08:29
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Paclitaxel in breast cancer
Debra Patt1, Michelle Gauthier, Sharon Giordano
1MD Anderson Cancer Center, 1515 Holcombe Blvd-10, Houston, TX 77030, USA.
Women'S Health (London, England)
|October 7, 2009
Summary
Paclitaxel, a key chemotherapy drug, is vital for treating metastatic breast cancer and node-positive breast cancer. This review covers its pharmacology, efficacy, and safety in breast cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Paclitaxel, derived from the Pacific yew tree, is a cornerstone chemotherapy agent.
- Approved in 1994, it remains crucial for metastatic breast cancer management.
- Current approvals include adjuvant treatment for node-positive breast cancer and metastatic disease.
Purpose of the Study:
- To review the pharmacology of paclitaxel.
- To summarize clinical efficacy data for paclitaxel in breast cancer.
- To assess the safety profile of paclitaxel for breast cancer patients.
Main Methods:
- Literature review of pharmacological data.
- Analysis of clinical trial data on efficacy.
- Compilation of safety and adverse event reports.
Main Results:
- Paclitaxel demonstrates significant efficacy in metastatic breast cancer.
- It is effective in adjuvant settings post-doxorubicin or for relapsed disease.
- Established safety profile with manageable side effects.
Conclusions:
- Paclitaxel is an indispensable chemotherapeutic agent for breast cancer.
- Its review confirms its established role in various treatment settings.
- Understanding its pharmacology, efficacy, and safety is critical for patient care.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...